Candida nivariensis Urinary Tract Infection in an Extremely Low-Birth-Weight Neonate

Abstract

We report on the diagnosis and treatment of a Candida nivariensis urinary tract infection in an extremely low-birth-weight neonate. The isolate was identified by MALDI-TOF technology and is the first known report of C. nivariensis in the neonatal or pediatric population. Treatment was initiated with amphotericin B deoxycholate and later completed with intravenous fluconazole following susceptibility results.

Keywords

neonate - urinary tract infection - Candida nivariensis - fungal - candiduria

• References

• 1 Botero-Calderon L, Benjamin Jr DK, Cohen-Wolkowiez M. Advances in the treatment of invasive neonatal candidiasis. Expert Opin Pharmacother 2015; 16 (07) 1035-1048
• 2 Kelly MS, Benjamin Jr DK, Smith PB. The epidemiology and diagnosis of invasive candidiasis among premature infants. Clin Perinatol 2015; 42 (01) 105-117 ; viii–ix
• 3 Alcoba-Flórez J, Méndez-Alvarez S, Cano J, Guarro J, Pérez-Roth E, del Pilar Arévalo M. Phenotypic and molecular characterization of Candida nivariensis sp. nov., a possible new opportunistic fungus. J Clin Microbiol 2005; 43 (08) 4107-4111
• 4 Fujita S, Senda Y, Okusi T. , et al. Catheter-related fungemia due to fluconazole-resistant Candida nivariensis. J Clin Microbiol 2007; 45 (10) 3459-3461
• 5 Gorton RL, Jones GL, Kibbler CC, Collier S. Candida nivariensis isolated from a renal transplant patient with persistent candiduria-molecular identification using ITS PCR and MALDI-TOF. Med Mycol Case Rep 2013; 2: 156-158
• 6 Pappas PG, Kauffman CA, Andes DR. , et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62 (04) e1-e50
• 7 Borman AM, Petch R, Linton CJ, Palmer MD, Bridge PD, Johnson EM. Candida nivariensis, an emerging pathogenic fungus with multidrug resistance to antifungal agents. J Clin Microbiol 2008; 46 (03) 933-938
• 8 Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother 2002; 46 (03) 828-833
• 9 Turkova A, Roilides E, Sharland M. Amphotericin B in neonates: deoxycholate or lipid formulation as first-line therapy - is there a ‘right’ choice?. Curr Opin Infect Dis 2011; 24 (02) 163-171
• 10 Singhal N, Kumar M, Kanaujia PK, Virdi JS. MALDI-TOF mass spectrometry: an emerging technology for microbial identification and diagnosis. Front Microbiol 2015; 6: 791-807